CDER tweaks Ozem­pic’s post-mar­ket­ing la­bel to in­clude risk for GI dis­or­der

CDER has added two post-mar­ket­ing caveats to the la­bel of No­vo Nordisk’s block­buster di­a­betes drug Ozem­pic, in­clud­ing a warn­ing for a con­di­tion re­lat­ed to a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER